Use of a polymorph of flibanserin for treating disease

• US 20050159430A1
• Filed: 03/14/2005
• Published: 07/21/2005
• Est. Priority Date: 08/02/2001
• Status: Abandoned Application

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: BIDACHEM S.p.A. (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Ezhaya, Antoine, Bombarda, Carlo, Dubini, Enrica
• Application Number:
  US11/079,070
• Publication Number:
  US 20050159430A1
• Time in Patent Office: Days
• US Class Current: 514/254.60
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 233/26 Radicals substituted by carbon atoms having three bonds to hetero atoms
• CPC Class Codes: C07D 235/26 Oxygen atoms
• CPC Class Codes: C07D 403/06 linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

Claims

1. ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT_1A or 5-HT₂-receptors in a patient, comprising administering to said patient a therapeutically effective amount of a crystalline polymorph, designated form A, of flibanserin 1,

2. ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT_1A or 5-HT₂-receptors in a patient, comprising administering to said patient a therapeutically effective amount of flibanserin 1 comprising form A according to claim 1.

5. ) A method for treating a disease selected from depression, schizophrenia, Parkinson'"'"'s, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of form A according to claim 1.

6. ) A method for treating a disease selected from depression, schizophrenia, Parkinson'"'"'s, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of flibanserin 1 comprising form A according to claim 1.

3. ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT_1A or 5-HT₂-receptors in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by the following X-ray powder diffraction pattern:

7. ) A method for treating a disease selected from depression, schizophrenia, Parkinson'"'"'s, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by the X-ray powder diffraction pattern according to claim 3.

4. ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT_1A or 5-HT₂-receptors in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by having an X-ray powder diffraction pattern as shown in FIG. 1.

8. ) A method for treating a disease selected from depression, schizophrenia, Parkinson'"'"'s, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by having an X-ray powder diffraction pattern as shown in FIG. 1.